A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease

Table 1

The basic characteristics of studies included in meta-analysis.

First author	Publication date	Type	N^$	Average age	Outcome	Follow-up time	Minor score
Hinojosa et al. [16]	2007	n-rct	22	37.4	23% (complete closure of all fistulas); 41% (experienced fistula improvement, 50%)	4 w	11
Colombel et al. [13]	2009	rct	70	37.1	40% (complete fistula closure)	56 w	18
Lichtiger et al. [17]	2010	n-rct	88	40.8	40.9% (complete fistula healing)	36 w	12
Dewint et al. [15]	2014	rct	39	39.3	47% : 50% reduction, 33% : 100% reduction	24 w	18
Castaño-Milla et al. [12]	2015	n-rct	46	36.5	41% remission, 8% partial response	12 m^#	12
Panaccione et al. [23]	2011	n-rct	68	37	40% complete fistula closure	24 w^#	12
Rizzello et al. [26]	2009	n-rct	46	35.7	24% complete fistula closure	24 w	12

^$Case load; 100% reduction/remission: complete closure of all fistulas that were draining at baseline and 50% reduction/partial response: ≥50% decrease in the number of fistulas that were draining at baseline; ^#m: month and w: week.